Compare ADMA Biologics Inc (ADMA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vanguard S&P 500 ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Vanguard S&P 500 ETF trades at $683.84. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | VOO | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $698.29 |
52-Week Low | $7.60 | $570.23 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
VOO, the Vanguard S&P 500 ETF, trades at $690.58, up 0.87% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the S&P 500, offering broad exposure to large-cap U.S. equities. Recent news highlights sector rotation and AI-driven market volatility, with strategists projecting further index gains. A dividend of $1.96 is scheduled for late June 2026.
The outlook for VOO remains positive given its diversification and the S&P 500's earnings momentum, though risks include tech sector concentration and potential market corrections. Long-term investors may find value in its low-cost, passive approach to U.S. equity exposure despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
